Literature DB >> 8051746

Patient age as a prognostic factor in prostate cancer.

H Grönberg1, J E Damber, H Jonsson, P Lenner.   

Abstract

Whether patient age per se is a prognostic factor of significance in prostate cancer is controversial. To investigate this issue age-specific relative survival was analyzed, and the number of years lost due to this disease was calculated in a large and unselected cohort of 6,890 prostate cancer patients diagnosed between 1971 and 1987 in the northern region of Sweden. The tumor grade was derived from filed notification forms, which showed 26.4% well (grade 1), 40.0% moderately (grade 2) and 17.7% poorly (grade 3) differentiated tumors. There was an overrepresentation of grade 3 tumors among the youngest patients. The age-specific relative survival rate did not differ significantly among different age groups and slight differences almost vanished when adjusting for tumor grade. This finding does not support the view that tumors appearing in younger patients are more aggressive per se. However, loss of life expectancy differed significantly among all age classes and in all 3 grades. In patients with grade 1 tumors the years lost due to prostate cancer ranged from 11.0 to 1.2 in the youngest and oldest age strata, even though the relative survival was approximately 0.70 in all age classes. It was concluded that even if relative survival is constant with patient age, the absolute impact of prostate cancer at different ages varied substantially as indicated by loss of life expectancy. This finding might indicate that younger prostate cancer patients should be given more aggressive treatment than older patients.

Entities:  

Mesh:

Year:  1994        PMID: 8051746     DOI: 10.1016/s0022-5347(17)32601-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

Review 1.  Prostate cancer: 2. Natural history.

Authors:  R K Nam; M A Jewett; M D Krahn
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

2.  Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation.

Authors:  Mamatha Damodarasamy; Robert B Vernon; Christina K Chan; Stephen R Plymate; Thomas N Wight; May J Reed
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-08-15       Impact factor: 2.416

3.  Does screening for prostate cancer identify clinically important disease?

Authors:  M R Feneley
Journal:  Ann R Coll Surg Engl       Date:  1999-05       Impact factor: 1.891

Review 4.  Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.

Authors:  Cynthia C Sprenger; Stephen R Plymate; May J Reed
Journal:  Int J Cancer       Date:  2010-10-08       Impact factor: 7.396

Review 5.  Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate.

Authors:  H B Carter; J I Epstein
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

6.  Prostate Cancer: How Young is too Young?

Authors:  Sahil Gupta; Arjun Gupta; Ashish K Saini; Kaustav Majumder; Kalpana Sinha; Anurag Chahal
Journal:  Curr Urol       Date:  2016-12-26

Review 7.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

8.  Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer.

Authors:  Chao-Yu Hsu; Steven Joniau; Raymond Oyen; Tania Roskams; Hein Van Poppel
Journal:  Asian J Androl       Date:  2008-12-15       Impact factor: 3.285

9.  Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Valentino Bettinardi; Luigi Gianolli; Vincenzo Scattoni; Cesare Cozzarini; Nadia Di Muzio; Patrizio Rigatti; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-15       Impact factor: 9.236

10.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.